207 related articles for article (PubMed ID: 27663394)
1. Modulating Immunosuppression in the Intrapleural Space of Malignant Pleural Mesothelioma and Predictive Biomarkers to Guide Treatment Decisions.
Wong RM
J Thorac Oncol; 2016 Oct; 11(10):1602-3. PubMed ID: 27663394
[No Abstract] [Full Text] [Related]
2. E-cadherin in mesothelioma.
Jeffers M
Hum Pathol; 1996 Nov; 27(11):1245-6. PubMed ID: 8912839
[No Abstract] [Full Text] [Related]
3. Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials.
Mohamed H; Eltobgy M; Abdel-Rahman O
Anticancer Agents Med Chem; 2017; 17(9):1228-1233. PubMed ID: 28042777
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis.
Gao R; Wang F; Wang Z; Wu Y; Xu L; Qin Y; Shi H; Tong Z
Medicine (Baltimore); 2019 Apr; 98(14):e14979. PubMed ID: 30946324
[TBL] [Abstract][Full Text] [Related]
5. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
Cappellesso R; Galasso M; Nicolè L; Dabrilli P; Volinia S; Fassina A
Cancer Cytopathol; 2017 Aug; 125(8):635-643. PubMed ID: 28449331
[TBL] [Abstract][Full Text] [Related]
6. Novel therapies for malignant pleural mesothelioma.
Scherpereel A; Wallyn F; Albelda SM; Munck C
Lancet Oncol; 2018 Mar; 19(3):e161-e172. PubMed ID: 29508763
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers and prognostic factors for malignant pleural mesothelioma.
Vigneri P; Martorana F; Manzella L; Stella S
Future Oncol; 2015; 11(24 Suppl):29-33. PubMed ID: 26638920
[TBL] [Abstract][Full Text] [Related]
8. Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?
Signorelli D; Macerelli M; Proto C; Vitali M; Cona MS; Agustoni F; Zilembo N; Platania M; Trama A; Gallucci R; Ganzinelli M; Pelosi G; Pastorino U; de Braud F; Garassino MC; Lo Russo G
Tumori; 2016; 102(1):18-30. PubMed ID: 26481865
[TBL] [Abstract][Full Text] [Related]
9. Is There Room for Second-Line Treatment of Pleural Malignant Mesothelioma?
Addeo A; Buffoni L; Di Maio M
JAMA Oncol; 2017 Sep; 3(9):1170-1171. PubMed ID: 28114625
[No Abstract] [Full Text] [Related]
10. Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients.
Lievense LA; Bezemer K; Cornelissen R; Kaijen-Lambers ME; Hegmans JP; Aerts JG
Lung Cancer; 2017 May; 107():36-40. PubMed ID: 27168021
[TBL] [Abstract][Full Text] [Related]
11. Cytoplasmic MTAP expression loss detected by immunohistochemistry correlates with 9p21 homozygous deletion detected by FISH in pleural effusion cytology of mesothelioma.
Hamasaki M; Kinoshita Y; Yoshimura M; Matsumoto S; Kamei T; Hiroshima K; Sato A; Tsujimura T; Kawahara K; Nabeshima K
Histopathology; 2019 Jul; 75(1):153-155. PubMed ID: 30957899
[No Abstract] [Full Text] [Related]
12. [Diagnostic value of tissue polypeptide antigen in pleural effusions with malignant pleural mesothelioma].
Tokuyama T; Yoneda T; Hamada K; Yoshikawa M; Fu A; Tomoda K; Nakaya M; Narita N; Tamura M; Kitamura K
Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Jan; 33(1):39-43. PubMed ID: 7699966
[TBL] [Abstract][Full Text] [Related]
13. Intrapleural Urokinase Directly Under Medical Thoracoscopy for the Diagnosis of Malignant Pleural Mesothelioma With Severe Multiloculated Pleural Effusions.
Terashita S; Kawachi H; Horikawa S; Noguchi S; Ikeue T; Sugita T
J Bronchology Interv Pulmonol; 2019 Apr; 26(2):e26-e27. PubMed ID: 30908399
[No Abstract] [Full Text] [Related]
14. Advances in the biology of malignant pleural mesothelioma.
Zucali PA; Ceresoli GL; De Vincenzo F; Simonelli M; Lorenzi E; Gianoncelli L; Santoro A
Cancer Treat Rev; 2011 Nov; 37(7):543-58. PubMed ID: 21288646
[TBL] [Abstract][Full Text] [Related]
15. Deciduoid pleural mesothelioma in an adolescent.
Arango-Tomás E; Algar-Algar FJ; Salvatierra Velázquez A
Arch Bronconeumol; 2013 May; 49(5):218-9. PubMed ID: 23265622
[No Abstract] [Full Text] [Related]
16. Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma.
Fontana V; Pistillo MP; Vigani A; Canessa PA; Berisso G; Giannoni U; Ferro P; Franceschini MC; Carosio R; Tonarelli M; Rossi C; Dessanti P; Roncella S
Anticancer Res; 2019 Sep; 39(9):5219-5223. PubMed ID: 31519636
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of medical thoracoscopy in malignant pleural effusion.
Wu YB; Xu LL; Wang XJ; Wang Z; Zhang J; Tong ZH; Shi HZ
BMC Pulm Med; 2017 Aug; 17(1):109. PubMed ID: 28778184
[TBL] [Abstract][Full Text] [Related]
18. Adenosine Deaminase in Pleural Effusion and Its Relationship with Clinical Parameters in Patients with Malignant Pleural Mesothelioma.
Nakajima Y; Kuribayashi K; Ishigaki H; Tada A; Negi Y; Minami T; Takahashi R; Doi H; Kitajima K; Yokoi T; Kijima T
Cancer Invest; 2020 Jul; 38(6):356-364. PubMed ID: 32468861
[TBL] [Abstract][Full Text] [Related]
19. High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma. Clinical observations and pharmacokinetic analyses.
Lerza R; Esposito M; Vannozzi M; Bottino GB; Bogliolo G; Pannacciulli I
Cancer; 1994 Jan; 73(1):79-84. PubMed ID: 8275441
[TBL] [Abstract][Full Text] [Related]
20. Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.
Kawai T; Greenberg SD; Truong LD; Mattioli CA; Klima M; Titus JL
Am J Pathol; 1988 Feb; 130(2):401-10. PubMed ID: 2449084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]